| operative approach | n | median survival (months) | 5-year survival rate | p-value |
---|---|---|---|---|---|
total | TT | 46 | 16 | 13.6% | 0.018 |
 | TH | 103 | 24 | 32.1% |  |
curative (R0) | TT | 36 | 17 | 17.6% | 0.045 |
 | TH | 94 | 28 | 35.1% |  |
palliative (R1) | TT | 10 | 9 | - | 0.778 |
 | TH | 8 | 8 | - |  |
R0 pN0 | TT | 9 | 27 | 22.2% | 0.072 |
 | TH | 40 | 67 | 54.1% |  |
R0 pN1 | TT | 26 | 14 | 14.3% | 0.430 a |
 | <19 thor. LN | 12 | 17 | 16.7% | 0.829 b |
 | >/ = 19 thor. LN | 14 | 8 | - |  |
 | TH | 51 | 16 | 22,4% | 0.703 c |
R0 pN1 T1-2 | TT | 4 | 14 | 25.0% | 0.357 |
 | TH | 21 | 28 | 33.3% |  |
R0 pN1 T3-4 | TT | 22 | 9 | 12.2% | 0.793 |
 | TH | 30 | 10 | - |  |
R0 pN1 ASA 1–2 | TT | 11 | 16 | 20.0% | 0.345 |
 | TH | 23 | 19 | 33.3% |  |
R0pN1 ASA 3–4 | TT | 15 | 9 | 10.3% | 0.999 |
 | TH | 25 | 10 | - |  |
R0 middle third | TT | 4 | 5 | 25% | 0.931 |
(tumor localization) | TH | 8 | 24 | 15% | Â |
R0 lower third | TT | 32 | 17 | 17.1% | 0.044 |
(tumor localization) | TH | 86 | 30 | 37.9% | Â |